Whereas progressive supranuclear palsy, often referred to as PSP, and corticobasal degeneration, often referred to as CBD, are rare, adult onset, rapidly progressing neurodegenerative disorders that affect multiple areas of the brain and cause complex symptoms and care needs;

Whereas, although some symptoms may appear similar to those of other neurological diagnoses like Parkinson’s disease and frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration are distinct diseases with their own unique trajectories and care needs;

Whereas, while estimates vary and the conditions are frequently misdiagnosed, approximately 30,000 Americans are living with progressive supranuclear palsy and 2,000 Americans are living with corticobasal degeneration;

Whereas delays in the accurate diagnosis of progressive supranuclear palsy and corticobasal degeneration and access to neurology professionals specialized in these diseases are common and cause confusion, anxiety, and frustration among patients;

Whereas progressive supranuclear palsy and corticobasal degeneration can cause significant difficulty with movement, balance, speech, swallowing, cognition, vision, mood, and a variety of other complex symptoms;

Whereas progressive supranuclear palsy and corticobasal degeneration are aggressive in their progression, with most individuals becoming dependent on care in 3 to 4 years and having an overall life expectancy of 7 to 8 years from symptom onset;

Whereas there are currently no disease-modifying treatments for progressive supranuclear palsy or corticobasal degeneration;

Whereas more research is needed to understand the roles of environmental factors and genetics in why people develop progressive supranuclear palsy and corticobasal degeneration;

Whereas there are countless family caregivers, friends, and loved ones whose lives are greatly affected by progressive supranuclear palsy and corticobasal degeneration;

Whereas additional research, support services, and education are needed to maintain quality of life for those affected by the disease, to develop better treatments and prevention of complications, and to find cures for progressive supranuclear palsy and corticobasal degeneration; and

Whereas the designation of the month of May 2026 as Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month will benefit individuals diagnosed with the diseases, families, healthcare professionals, and communities across the country and will further bolster awareness of the diseases: Now, therefore, be it